|
Sep 10
|
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
|
|
Sep 10
|
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
|
|
Sep 9
|
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
|
|
Aug 8
|
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
|
|
Jul 25
|
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
|
|
May 10
|
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
|
|
May 9
|
Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 9
|
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
|
|
May 8
|
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
|
|
Apr 29
|
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
|
|
Mar 6
|
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 5
|
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
|
|
Sep 25
|
Insider Traders Lose US$114k As Viridian Therapeutics Drops
|
|
Sep 25
|
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
|
|
Sep 7
|
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
|